RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR (CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ)

被引：0
|
作者：
Rao, V. U. [1 ,2 ]
Pavlov, A. [3 ]
Klearman, M. [1 ]
Musselman, D. [1 ]
Giles, J. T. [4 ]
Bathon, J. M. [4 ]
Sattar, N. [5 ]
Lee, J. S. [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Indiana Heart Phys, Indianapolis, IN USA
[3] Everest, Toronto, ON, Canada
[4] Columbia Univ, New York, NY USA
[5] U Glasgow, Glasgow, Lanark, Scotland
[6] Roche, Nutley, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2594
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：356 / 357
页数：2
相关论文
共 50 条
  • [1] Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon T.
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S642 - S642
  • [2] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, Dave
    Giles, Jon
    Bathon, Joan
    Sattar, Naveed
    Lee, Janet
    [J]. RHEUMATOLOGY, 2012, 51 : 138 - 138
  • [3] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH THE INTERLEUKIN-6 RECEPTOR INHIBITOR TOCILIZUMAB
    Rao, Vijay Udyavar
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1648 - E1648
  • [4] MAJOR ADVERSE CARDIOVASCULAR EVENTS: RISK FACTORS IN PATIENTS WITH RA TREATED WITH TOFACITINIB
    Charles-Schoeman, C.
    Valdez, H.
    Soma, K.
    Hwang, L.
    DeMasi, R.
    Boy, M.
    McInnes, I. B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1034 - 1035
  • [5] Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
    Charles-Schoeman, Christina
    Valdez, Hernan
    Soma, Koshika
    Hwang, Lie-Ju
    DeMasi, Ryan
    Boy, Mary
    McInnes, Iain B.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
    Mal, Kheraj
    Kumar, Ratan
    Mansoor, Farah
    Kaur, Navneet
    Kumar, Anil
    Memon, Sidra
    Rizwan, Amber
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [7] Factors influencing treatment maintenance of SC and IV tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in real life
    Vauleon, Tiphaine
    Pau, David
    Darloy, Jean
    Flipo, Rene-Marc
    Segaud, Nicolas
    Eschard, Jean-Paul
    Gally, Samuel
    Niarra, Ralph
    Idier, Isabelle
    Baudens, Guy
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 407 - 407
  • [8] An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
    Rao, Vijay U.
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon T.
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67 (02) : 372 - 380
  • [9] Tocilizumab (TCZ) Long-Term Efficacy in Rheumatoid Arthritis (RA) Patients (pts) Treated up to 3.7 Years
    Khraishi, Majed
    Haraoui, Boulos
    Alten, Rieke
    Gomez-Reino, Juan
    Rizzo, Warren
    Schechtman, Joy
    Kahan, Andre
    Vernon, Emma
    Taylor, Monet
    Smolen, Joseph
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1164 - 1164
  • [10] Risk of major adverse cardiovascular events in patients with rheumatoid arthritis using Janus Kinase inhibitors
    You, Seung-Hun
    Cho, Soo-Kyung
    Song, Yeo-Jin
    Sung, Yoon-Kyoung
    Jung, Sun-Young
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 521 - 522
12345